Updated:
PierianDx
PierianDx is a Salt Lake City firm providing clinical-grade genomic interpretation software for precision oncology. Serves 70+ healthcare systems.
PierianDx
PierianDx was founded to address the gap between genomic sequencing data and actionable clinical decision-making. The firm's platform, Clinical Genomics Workspace (CGW), integrates with hospital laboratory workflows to deliver standardized, CLIA-validated variant interpretations. PierianDx serves over 70 hospital systems and academic medical centers globally, including major US health networks and research institutions (per company materials). PierianDx's revenue model is primarily enterprise software licensing and per-test analysis fees for next-generation sequencing (NGS) panels. The firm covers solid tumors, hematologic malignancies, and hereditary cancers. Competitors include Tempus, Caris Life Sciences, and SOPHiA GENETICS. PierianDx has raised over $40M in venture debt and equity, including a $27M Series B round in 2018 led by health-tech investor Arboretum Ventures (per press releases). The company has not disclosed a direct investment arm or asset management function. PierianDx employs engineers, bioinformaticians, and board-certified geneticists. The firm's headquarters is in Salt Lake City, with additional operations and partnerships across North America. A significant event in the past 24 months: In 2024, PierianDx announced its CGW platform integration with Epic's electronic health record system at several large health systems (per company announcements). The firm has not disclosed plans for traditional asset management services. PierianDx's structural differentiator is its focus on clinical-grade, CLIA-certified interpretation — not just raw variant calling. While many competitors emphasize data volume or AI-only pipelines, PierianDx has built cross-disciplinary curation teams combining board-certified molecular pathologists and software engineers. This hybrid model places it closer to a laboratory professional-services firm than a pure technology company.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Salt Lake City
Corporate office
Salt Lake City, UT, United States
Sector focus
Frequently asked questions
Who runs investment decisions at PierianDx?
PierianDx is not structured as an investment firm — it is an enterprise software and clinical diagnostics company. Capital allocation decisions are made by the executive leadership, which has included CEO Dr. Kris Michelson as of its founding era. The firm's strategic direction is influenced by its board, which includes investors from Arboretum Ventures (per public records).
Does PierianDx manage capital for external allocators?
No. PierianDx is a clinical-genomics software and services company, not a fund manager or family office. It has raised venture capital and debt from outside investors but does not deploy third-party capital into other companies or assets.
How does PierianDx's platform differ from consumer genomics tools?
PierianDx focuses on clinical-grade interpretation for diagnostic use, meaning results are validated for use in treatment decision-making by physicians. Unlike 23andMe or similar consumer services, PierianDx's platform complies with CLIA and CAP laboratory standards and integrates into hospital electronic health records for oncology workflows.
What investment stages does PierianDx typically target?
PierianDx does not make external investments. The company itself has raised venture capital at the Series B stage (2018) and subsequent venture debt rounds. It operates as a growth-stage healthcare technology company.
Where does the underlying wealth come from?
PierianDx is a privately held company funded by venture capital and debt financing. No single family office or dynastic wealth has been publicly identified as the principal owner. Investors include Arboretum Ventures and other health-tech funds (per press releases).
Is PierianDx structured as a family office or does it operate more like a venture firm?
Neither — PierianDx is structured as a C corporation in the clinical software and diagnostics industry. It has no family-office operations, no permanent capital pool from a single wealthy family, and no fund management structure.
Does PierianDx have any philanthropic foundations or operating businesses?
No public philanthropic foundation has been reported under the PierianDx entity. The company operates only its core commercial business: clinical genomics interpretation software and related laboratory services.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: